帕立骨化醇对边疆少数民族地区MHD患者SHPT的疗效研究  

Efficacy of paricalcitol in the treatment of SHPT in maintenance phemodialysis patients in frontier minority areas

作　　者：杨家云 杨军 那杨艳 陈国庆 周竹[1] 杨秋燕 YANG Jia-yun;YANG Jun;NA Yang-yan;CHEN Guo-qing;ZHOU Zhu;YANG Qiu-yan(Department of Nephrology,the First Affiliated Hospital of Kunming Medical University,Yunnan Chronic Kidney Disease Clinical Medical Research Center,Kunming Yunnan 650032,China;Department of Nephrology,Lincang People s Hospital,Lincang Yunnan677000,China)

机构地区：[1]昆明医科大学第一附属医院肾内科,云南省慢性肾病临床医学研究中心,云南昆明650000 [2]云南省临沧市人民医院肾内科,云南临沧677000

出　　处：《云南医药》2022年第5期10-13,共4页Medicine and Pharmacy of Yunnan

基　　金：云南省慢性肾病临床医学研究中心专项(202102AA100060);临沧市科技创新人才培养项目。

摘　　要：目的研究帕立骨化醇治疗MHD患者SHPT的有效性。方法随机选取2021年3月1日至2022年2月28日临沧市人民医院MHD并SHPT的72例患者进行研究,并随机分成2组,实验组、对照组各36例。收集患者用药前信息及治疗开始4周、12周、24周的随访数据,同时采集合并用药及不良事件信息,通过对照分析帕立骨化醇治疗的有效性。结果实验组iPTH在治疗1~3月后稳步下降,临床症状缓解,总有效率94.44%,降低iPTH作用明显优于对照组,且在减少药物剂量后仍有维持作用,药物不良反应少,使用较为安全。观察实验组患者iPTH变化还发现经过治疗后iPTH的控制达标率由4周后的27.78%上升至24周后的47.22%,iPTH>585 pg/mL的未控制患者由30.56%降至7.78%,而对照组iPTH控制达标率基本没有明显的变化。结论帕立骨化醇能有效降低iPTH,改善SHPT的治疗效果,用药不良反应发生率较低,值得临床推广使用。Objective To study the efficacy of paricalcitol in the treatment of SHPT in patients with maintenance MHD.Methods 72 patients with MHD and SHPT Lincang People s Hospital from Mar.1st,2021 to Feb.28,2022 were randomly selected in the research,and randomly divided 36 patients for each in experimental and control groups.The pre-medication information of the patients and the follow-up data of 4 weeks,12 weeks and 24 weeks after the start of treatment were collected,and the drug combination and adverse evant information were collected too.The efficacy of paricalcitol treatment was analyzed by comparison.Results The iPTH in the experimental group decreased steadily after 1-3 months of treatment,the clinical symptoms were relieved,and the total effective rate was 94.44%.The iPTH reduction effect of the treatment group was significantly better than that of the control group,and it still maintained the effect after the drug dose was reduced.The drug had few adverse reactions and was safer to use.Observed the changes of iPTH in the experimental group that after treatment,the control rate of iPTH increased from 27.78%after 4 weeks to 47.22%after 24 weeks,the uncontrolled patients with iPTH greater than 585pg/mL decreased from 30.56%to 7.78%,and In the control group,there was basically no significant change in the compliance rate of iPTH control.Conclusions Paricalcitol can effectively reduce iPTH,improve the therapeutic effect of SHPT,and the incidence of adverse drug reactions is low,which is worthy of clinical promotion.

关 键 词：边疆少数民族地区 帕立骨化醇 继发性甲状旁腺机能亢进症 

分 类 号：R692.5[医药卫生—泌尿科学] R582.1[医药卫生—外科学]